NDAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2005
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
TYGACIL (tigecycline) by Pfizer. Approved for complicated intra-abdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia. First approved in 2005.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYGACIL (tigecycline) is a broad-spectrum intravenous tetracycline-class antibiotic approved in 2005 for complicated intra-abdominal infections, complicated skin and skin structure infections, and community-acquired bacterial pneumonia. It is effective against multidrug-resistant gram-positive and gram-negative bacteria, including carbapenem-resistant pathogens and non-tuberculous mycobacteria. The drug works by inhibiting bacterial protein synthesis, similar to other tetracyclines but with enhanced activity against resistant organisms.
$0.085MPart D
Peak4.4 years to LOETYGACIL remains at peak commercial maturity with stable Part D utilization, but the product faces significant generic pressure and declining market dynamics as LOE approaches in 4.5 years.
Mechanism of Action
Pharmacologic Class:
Tetracycline-class Antibacterial
Worked on TYGACIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.